Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Kajihara N, Kobayashi T, Otsuka R, Nio-Kobayashi J, Oshino T, Takahashi M, Imanishi S, Hashimoto A, Wada H, Seino KI. Kajihara N, et al. Among authors: imanishi s. Cancer Immunol Immunother. 2023 Apr;72(4):851-864. doi: 10.1007/s00262-022-03293-3. Epub 2022 Sep 14. Cancer Immunol Immunother. 2023. PMID: 36104597 Free PMC article.
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer.
Nakatsukasa K, Koyama H, Oouchi Y, Imanishi S, Mizuta N, Sakaguchi K, Fujita Y, Fujiwara I, Kotani T, Matsuda T, Fukuda K, Morita M, Kawakami S, Kadotani Y, Konishi E, Yanagisawa A, Taguchi T. Nakatsukasa K, et al. Among authors: imanishi s. Breast Cancer. 2017 Jan;24(1):63-68. doi: 10.1007/s12282-016-0666-7. Epub 2016 Jan 11. Breast Cancer. 2017. PMID: 26754092 Clinical Trial.
Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
Nakatsukasa K, Koyama H, Oouchi Y, Imanishi S, Mizuta N, Sakaguchi K, Fujita Y, Imai A, Okamoto A, Hamaoka A, Soushi M, Fujiwara I, Kotani T, Matsuda T, Fukuda K, Morita M, Kawakami S, Kadotani Y, Konishi E, Yanagisawa A, Goto M, Yamada K, Taguchi T. Nakatsukasa K, et al. Among authors: imanishi s. Breast Cancer. 2017 Jan;24(1):92-97. doi: 10.1007/s12282-016-0677-4. Epub 2016 Feb 13. Breast Cancer. 2017. PMID: 26874836 Clinical Trial.
[Production of ectopic stimulation].
Goto M, Imanishi S. Goto M, et al. Among authors: imanishi s. Nihon Rinsho. 1969 Oct;27(10):2441-9. Nihon Rinsho. 1969. PMID: 4901440 Review. Japanese. No abstract available.
A case of rectal metastasis of prostate cancer mimicking extramural growth-type rectal tumor.
Hike S, Endo S, Ota M, Ohira G, Maruyama M, Imanishi S, Maruyama T, Tochigi T, Amagai H, Shiraishi T, Hirata A, Mamiya H, Iwata M, Kakimoto A, Matsubara H. Hike S, et al. Among authors: imanishi s. J Surg Case Rep. 2024 May 18;2024(5):rjae314. doi: 10.1093/jscr/rjae314. eCollection 2024 May. J Surg Case Rep. 2024. PMID: 38764733 Free PMC article.
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression.
Inomata M, Minatoyama S, Takata N, Hayashi K, Hirai T, Seto Z, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Tobe K. Inomata M, et al. Among authors: imanishi s. Mol Clin Oncol. 2024 May 1;20(6):43. doi: 10.3892/mco.2024.2741. eCollection 2024 Jun. Mol Clin Oncol. 2024. PMID: 38756869 Free PMC article.
258 results